OBJECTIVE: There is reluctance to use glutamine-containing i.v. nutrition for neurosurgical patients, as this may result in elevated intracerebral glutamate levels, which are thought to be associated with neuronal injury and cell swelling, causing an increase in ICP and an unfavourable outcome. As general ICU patients benefit from i.v. glutamine supplementation in terms of reduced mortality and morbidity, neurosurgical patients might also be candidates for such treatment, if the possible relation between i.v. glutamine supplementation and a possible increase in cerebral glutamate could be sorted out. DESIGN AND SETTING: The study protocol had a crossover design with a 24h treatment period and a 24h placebo period in random order. Treatment was a glutamine containing dipeptide, L-alanyl-L-glutamine 200mg/ml, for 20h; placebo was saline. The rate of infusion was 0.125ml/kg/h, which is equal to 0.34g/kg of glutamine over the 20h period. Microdialysate was collected for analysis in 120min portions. The flow through the microdialysis catheter was 0.3microl/min. SUBJECTS:Patients with severe head trauma (GCS<or=8; n=15) on routine monitoring, including intracerebral microdialysis, were randomly assigned to treatment followed by placebo or placebo followed by treatment. MEASUREMENTS AND RESULTS:Glutamine infusion increased plasma glutamine concentration by 30%, but not plasma glutamate concentration. Intracerebral glutamate was unaffected in median values and in all individual patients. CONCLUSION:Intravenous glutamine in clinically relevant doses leaves cerebral glutamate unaffected. This opens the possibility of evaluating the effects of i.[Symbol: see text]v. glutamine supplementation upon outcome for neurosurgical ICU patients.
RCT Entities:
OBJECTIVE: There is reluctance to use glutamine-containing i.v. nutrition for neurosurgical patients, as this may result in elevated intracerebral glutamate levels, which are thought to be associated with neuronal injury and cell swelling, causing an increase in ICP and an unfavourable outcome. As general ICU patients benefit from i.v. glutamine supplementation in terms of reduced mortality and morbidity, neurosurgical patients might also be candidates for such treatment, if the possible relation between i.v. glutamine supplementation and a possible increase in cerebral glutamate could be sorted out. DESIGN AND SETTING: The study protocol had a crossover design with a 24h treatment period and a 24h placebo period in random order. Treatment was a glutamine containing dipeptide, L-alanyl-L-glutamine 200mg/ml, for 20h; placebo was saline. The rate of infusion was 0.125ml/kg/h, which is equal to 0.34g/kg of glutamine over the 20h period. Microdialysate was collected for analysis in 120min portions. The flow through the microdialysis catheter was 0.3microl/min. SUBJECTS:Patients with severe head trauma (GCS<or=8; n=15) on routine monitoring, including intracerebral microdialysis, were randomly assigned to treatment followed by placebo or placebo followed by treatment. MEASUREMENTS AND RESULTS: Glutamine infusion increased plasma glutamine concentration by 30%, but not plasma glutamate concentration. Intracerebral glutamate was unaffected in median values and in all individual patients. CONCLUSION: Intravenous glutamine in clinically relevant doses leaves cerebral glutamate unaffected. This opens the possibility of evaluating the effects of i.[Symbol: see text]v. glutamine supplementation upon outcome for neurosurgical ICU patients.
Authors: Donald W Marion; Ava Puccio; Stephen R Wisniewski; Patrick Kochanek; C Edward Dixon; Leann Bullian; Patricia Carlier Journal: Crit Care Med Date: 2002-12 Impact factor: 7.598
Authors: Christiane Goeters; Anke Wenn; Norbert Mertes; Carola Wempe; Hugo Van Aken; Peter Stehle; Hans-Georg Bone Journal: Crit Care Med Date: 2002-09 Impact factor: 7.598
Authors: R Svedjeholm; S Svensson; R Ekroth; I Milocco; F Nilsson; E Vinnars; J Wernerman Journal: Thorac Cardiovasc Surg Date: 1990-02 Impact factor: 1.827
Authors: Roman Hlatky; Alex B Valadka; J Clay Goodman; Charles F Contant; Claudia S Robertson Journal: J Neurotrauma Date: 2004-07 Impact factor: 5.269
Authors: Peter Andrews; Elie Azoulay; Massimo Antonelli; Laurent Brochard; Christian Brun-Buisson; Daniel De Backer; Geoffrey Dobb; Jean-Yves Fagon; Herwig Gerlach; Johan Groeneveld; Duncan Macrae; Jordi Mancebo; Philipp Metnitz; Stefano Nava; Jerôme Pugin; Michael Pinsky; Peter Radermacher; Christian Richard Journal: Intensive Care Med Date: 2006-12-19 Impact factor: 17.440
Authors: Lucia Salamanca-Cardona; Hardik Shah; Alex J Poot; Fabian M Correa; Valentina Di Gialleonardo; Hui Lui; Vesselin Z Miloushev; Kristin L Granlund; Sui S Tee; Justin R Cross; Craig B Thompson; Kayvan R Keshari Journal: Cell Metab Date: 2017-10-19 Impact factor: 31.373